Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Other Non Operating Income (2019 - 2023)

C4 Therapeutics has reported Other Non Operating Income over the past 3 years, most recently at -$621000.0 for Q3 2023.

  • For Q3 2023, Other Non Operating Income changed N/A year-over-year to -$621000.0; the TTM value through Dec 2024 reached -$621000.0, changed 0.0%, while the annual FY2023 figure was -$621000.0, N/A changed from the prior year.
  • Other Non Operating Income for Q3 2023 was -$621000.0 at C4 Therapeutics, down from $43000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $43000.0 in Q3 2020 and troughed at -$621000.0 in Q3 2023.
  • A 3-year average of -$193000.0 and a median of -$1000.0 in 2019 define the central range for Other Non Operating Income.
  • On a YoY basis, Other Non Operating Income climbed as much as 4400.0% in 2020 and fell as far as 4400.0% in 2020.
  • Year by year, Other Non Operating Income stood at -$1000.0 in 2019, then skyrocketed by 4400.0% to $43000.0 in 2020, then plummeted by 1544.19% to -$621000.0 in 2023.
  • Business Quant data shows Other Non Operating Income for CCCC at -$621000.0 in Q3 2023, $43000.0 in Q3 2020, and -$1000.0 in Q3 2019.